Réaction #4867

ord-c50403bc6f784521a924357c892f597a

Conditions de réaction

Conditions détaillées
See reaction.notes.procedure_details.

Traitement

  1. 1
    workup.ADDITIONis added
  2. 2
    Autreat -30° to -35° C.
  3. 3
    workup.STIRRINGthe mixture is further stirred at the same temperature for 5 minutes
  4. 4
    Autreis prepared
  5. 5
    workup.DISSOLUTIONto dissolve
  6. 6
    workup.ADDITION) is added
  7. 7
    Autreat -35° to -30° C.
  8. 8
    workup.STIRRINGthe mixture is stirred at the same temperature for 10 minutes and at -30° to -10° C. for one hour
  9. 9
    ConcentrationThe mixture is concentrated to dryness under reduced pressure
  10. 10
    workup.ADDITION60 ml of 80% aqueous formic acid are added to the residue
  11. 11
    workup.STIRRINGthe aqueous mixture is stirred at room temperature for one hour
  12. 12
    workup.ADDITION50 ml of water are added
  13. 13
    FiltrationThen, insoluble materials are filtered off
  14. 14
    Lavagethe filtrate is washed with ethyl acetate
  15. 15
    Concentrationconcentrated to dryness under reduced pressure
  16. 16
    AutreThe residue thus obtained
  17. 17
    Autrechromatographed on a column of non-ionic polymer resin Diaion
  18. 18
    LavageThe column is washed with water
  19. 19
    Lavagefollowed by elution with 20% methanol
  20. 20
    workup.ADDITIONThe fractions containing the cephalosporin compound
  21. 21
    Autreare collected
  22. 22
    Concentrationconcentrated to dryness under reduced pressure
  23. 23
    workup.ADDITIONAcetone is added to the residue
  24. 24
    Autrethus obtained
  25. 25
    Filtrationthe resulting powder is collected by filtration

Mode opératoire

0.57 g of oxalyl chloride is added at -5° to 0° C. to 15 ml of chloroform containing 0.35 g of dimethylformamide, and the mixture is stirred at the same temperature for 15 minutes. A mixture of 1.54 g of (Z)-2-(2-tritylaminothiazol-4-yl)-2-[(2-pyrrolidon-3-yl)oxyimino]acetic acid, 0.3 g of triethylamine and 15 ml of chloroform is added to said mixture at -30° to -35° C., and the mixture is further stirred at the same temperature for 5 minutes. Then, a solution of 7β-amino-3-(1-pyridinio-methyl)-3-cephem-4-carboxylate in chloroform (said solution is prepared by suspending 1.82 g of the dihydrochloride of said cephem compound in 10 ml of chloroform and adding 4 ml of N,O-bis(trimethylsilyl)acetamide thereto to dissolve said salt therein) is added to said mixture at -35° to -30° C., and the mixture is stirred at the same temperature for 10 minutes and at -30° to -10° C. for one hour. The mixture is concentrated to dryness under reduced pressure. 60 ml of 80% aqueous formic acid are added to the residue, and the aqueous mixture is stirred at room temperature for one hour. 50 ml of water are added to said aqueous mixture. Then, insoluble materials are filtered off, and the filtrate is washed with ethyl acetate and concentrated to dryness under reduced pressure. The residue thus obtained is dissolved in water and chromatographed on a column of non-ionic polymer resin Diaion HP-20 (registered trade mark, manufactured by Mitsubishi Chemical Industries Ltd., Japan). The column is washed with water, followed by elution with 20% methanol. The fractions containing the cephalosporin compound are collected and concentrated to dryness under reduced pressure. Acetone is added to the residue thus obtained, and the resulting powder is collected by filtration. 0.84 g of 7β-{(Z)-2-(2-aminothiazol-4-yl)-2-[(2-pyrrolidon-3-yl)oxyimino]acetamido}-3-(1-pyridiniomethyl)-3-cephem-4-carboxylate is obtained.

Source

DOI: 10.6084/m9.figshare.5104873.v1Brevet: US04727071uspto-grants-1988_02